| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8793979 | Ophthalmology | 2018 | 7 Pages | 
Abstract
												These analyses from real-world data indicate that anti-VEGF intravitreous injections are associated with a small but statistically significant decrease in IOP over time. A proportion of patients, on average 2.6%, experienced a sustained clinically significant IOP rise with these drugs overall compared with 1.5% in the fellow untreated eyes. However, such an increase was not seen with aflibercept.
											Keywords
												Intelligent Research in SightDMEGLMIVANVEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMDAMDCATTiOpDiabetic macular edemaBRAVOage-related macular degenerationDiabetic Retinopathy Clinical Research NetworkIrisVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressureAnchorMarinaGeneralized linear modelViewCruiseCopernicusGalileo
												Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Ophthalmology
												
											Authors
												Elizabeth A. MD, Kevin M. MS, Cynthia G. MD, Catherine N. PhD, Flora MD, Mathew W. MD, PhD, 
											